Mesoblast Limited · ASX:MSB

Mesoblast — Investor Day (November 2026)

20 slides from Mesoblast's investor day presentation, Nov 16, 2026

  1. Slide 1: Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases

    rsonal use only Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases ASX Investor Day November 2026 ASX: MSB; Nasdaq: MESO

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements rsonal use only This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual res

  3. Slide 3: FY2026: Highlights for the Year and Delivery of Major Milestones

    FY2026: Highlights for the Year and Delivery of Major Milestones Successful first year for U.S. commercial launch of RYONCIL • FY2026 net revenue US$115M rsonal use only • Gross profit on total sales, excluding amortization expense, was US$110M Major milestones achieved ✓ Completed 350 patients trea

  4. Slide 4: Our 'MOAT' – Our Market Leadership Position

    Our ‘MOAT’ – Our Market Leadership Position ✓ Global IP portfolio >1,100 patents and patent applications provide protection through >2044 ✓ Dominant IP underpins a scalable commercial business model for cell therapy products rsonal use only ✓ First mover advantage – RYONCIL is the first and only MSC

  5. Slide 5: Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies

    Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies rsonal use only Ryoncil® Only FDA Approved Rexlemesteocel-L the Engine for Commercial Capability MSC, Successful First US Launch Blockbuster Opportunities Net revenue US$115M in FY2026 – Infrastructure to support product Rexlemestrocel

  6. Slide 6: Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio

    Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio Assets Wholly Owned and Unencumbered in U.S. Markets TAM ~US$1B rsonal use only TAM >US$1B TAM >US$1B TAM >US$10B TAM >US$10B This chart is figurative and does not purport to show individual trial progress within a clinical pro

  7. Slide 7: RYONCIL: Steroid-Refractory Acute Graft Versus Host Disease

    rsonal use only RYONCIL® Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) 7

  8. Slide 8: Potential Market for RYONCIL Label Extension in Adults

    Potential Market for RYONCIL Label Extension as Part of Second-line Regimen Combined with Ruxolitinib in Adults with Grade III/IV aGvHD • >2,000 adults annually in U.S. with SR-aGvHD of which ~50% have Grade III/IV disease rsonal use only • Registration trial: 180 Grade III/IV SR-aGvHD adults random

  9. Slide 9: Rexlemestrocel-L: Chronic Low Back Pain due to Degenerative Disc Disease

    rsonal use only Rexlemestrocel-L Chronic Low Back Pain due to Degenerative Disc Disease (CLBP)

  10. Slide 10: Phase 3 Trial to Reduce Inflammation & Pain in Degenerative Disc Disease

    Phase 3 trial to Reduce Inflammation & Pain in Degenerative Disc Disease Targeted, minimally invasive delivery of rexlemestrocel-L to the degenerated disc rsonal use only Major Milestones to Commercial Launch 1 P3 trial 350 patients fully enrolled 2 Primary endpoint: 12-month pain reduction Secondar

  11. Slide 11: The Patient Treatment Journey

    The Patient Treatment Journey ~7M US patients have moderate / severe DDD within 5 years of diagnosis that is refractory to medical therapies including opioids rsonal use only Rexlemestrocel-L targeting moderate-to-severe CLBP Conservative Opioid Interventional Treatments Surgery Analgesics Therapies

  12. Slide 12: Rexlemestrocel-L: Heart Failure

    rsonal use only Rexlemestrocel-L Heart Failure

  13. Slide 13: Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism

    Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism LVAD BLA approval for rexlemestrocel-L can open label extension potential in two additional blockbuster indications with same mechanism of action Group 2 Pulmonary rsonal use only End-Stage HFrEF NYHA Class II/III Hypertension with LV

  14. Slide 14: Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs

    Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs by Reversing Endothelial Dysfunction of GI Blood Vessels Due to Inflammation LVAD II: 6-Month Rate of Major Mucosal Bleeding Events (MMBE) rsonal use only Control Rexlemestrocel-L Subjects from LVAD II Study Nominal (MMBE ra

  15. Slide 15: Group 2 Pulmonary Hypertension (Due to LV Dysfunction)

    Group 2 Pulmonary Hypertension (Due to LV Dysfunction) Left-heart disease raises pulmonary pressure and right ventricular load Left-heart disease Pulmonary venous Right ventricular strain rsonal use only hypertension LV or valve disease raises Pressure backs up into Higher pulmonary left atrial pres

  16. Slide 16: Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension

    Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension in DREAM-HF Trial • In the DREAM-HF population with HFrEF, 219 patients had established Group 2 Pulmonary rsonal use only Hypertension, defined by pulmonary artery systolic pressure (PASP) >35 mmHg, • Across all 219 pati

  17. Slide 17: Group 2 PH: A Large Unmet Need with No Approved Drugs

    Group 2 PH: A Large Unmet Need with No Approved Drugs Left heart disease is the most common cause of pulmonary hypertension, creating a substantial addressable population Total Addressable Market for Rexlemestrocel-L rsonal use only 2 GROUP 2 PH - CLINICAL CONTEXT Illustrative patient funnel | Unite

  18. Slide 18: In Summary

    rsonal use only In Summary 18

  19. Slide 19: Summary of Major Milestones

    Summary of Major Milestones Commercial growth and label expansion for RYONCIL, alongside advancement of rexlemestrocel-L blockbuster programs COMMERCIAL + LABEL BLOCKBUSTER PROGRAM BLOCKBUSTER PROGRAM rsonal use only 1 2 3 EXPANSION RYONCIL® Chronic low back pain Advanced & End-stage heart (remestem

  20. Slide 20: Thank You

    rsonal use only Thank You

Mesoblast — Investor Day (November 2026) on 6ix